NCT06676982招募中1 期
Clinical Trial of Autologous CD19 CAR-T Cells (CNCT19) Therapy for Advanced Hepatocellular Carcinoma
Zhejiang University2 个研究点 分布在 1 个国家目标入组 12 人开始时间: 2025年1月10日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 12
- 试验地点
- 2
- 主要终点
- Dose limiting toxicity (DLT)
研究概览
简要总结
A phase I clinical study of the safety and tolerability, efficacy of CNCT19 CAR T-cell therapy in patients with advanced hepatocellular carcinoma hepatocellular carcinoma.
详细描述
This is a single-arm, dose-escalation, open, exploratory clinical study to evaluate the safety and tolerability, preliminary efficacy and PK/PD haracteristics of CNCT19 CAR T-cell therapy in the treatment of advanced hepatocellular carcinoma.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Aged 18 to 80 years, male or female;
- •Subjects voluntarily participated in the research and signed the Informed Consent Form (ICF) by themselves or their guardians;
- •Pathologically diagnosed with hepatocellular carcinoma, patients with China liver Cancer Staging (CNLC) stageII-III.;
- •HCC patients who are not suitable for surgical resection or local treatment (including ablation therapy, interventional therapy, and radiation therapy), or who experience recurrence or progression after surgery and/or local treatment, and who have previously received at least second-line systematic standardized treatment and have progressed or are intolerant to it;
- •According to RECIST 1.1 standard, there should be at least one measurable tumor lesion;
- •Tumor samples that meet the requirements (paraffin blocks or unstained sections with a quantity that meets the testing requirements specified in this study) within 2 years, and have CD19/CD68 double positive cells detected by immunohistochemistry or immunofluorescence;
- •Child-Pugh ≤ 7 and no history of hepatic encephalopathy;
- •ECOG 0-1;
- •Expected survival period ≥ 12 weeks;
- •The toxicity caused by previous treatment has stabilized or recovered to ≤ level 1 (except for cases judged by the researcher to be clinically insignificant)
排除标准
- •Active brain metastasis;
- •Patients who have received or are waiting for organ transplantation;
- •Active autoimmune diseases that require systemic immunosuppressive therapy within the past 2 years, such as systemic lupus erythematosus, rheumatoid arthritis, ulcerative colitis, etc;
- •Researchers evaluated that the proportion of intrahepatic tumors is greater than 50% of the entire liver; Or there may be tumor thrombus formation in the main portal vein, or tumor thrombus invasion into the mesenteric vein/inferior vena cava;
- •Use any of the following drugs or treatment methods within the specified time before cell collection: a Received local treatments such as surgical intervention, radiation therapy, ablation, etc. for the studied disease within 4 weeks prior to cell collection; b. Patients who have undergone major surgical procedures or significant trauma within 4 weeks prior to cell collection, or who are expected to undergo major surgery during the study period; c. Received immunotherapy such as anti-PD-1 and PD-L1 within one week prior to cell collection; d. Received chemotherapy drugs or targeted therapy such as sorafenib, regorafenib, lenvatinib within 2 weeks prior to cell collection; e. Used therapeutic doses of corticosteroids within 3 days prior to cell collection, but allowed to use topical and inhaled corticosteroids;
- •Within the past 5 years or simultaneously with other incurable malignant tumors, except for cervical cancer in situ, basal cell carcinoma of the skin, and ductal carcinoma in situ of the breast;
- •Individuals who have received other cell therapies or gene modified cell therapies in the past;
- •Central nervous system diseases that have clinical significance in the past or screening, such as epilepsy, epileptic seizures, cerebrovascular disease (ischemia/hemorrhage/cerebral infarction), cerebral edema, reversible posterior white matter encephalopathy, paralysis, aphasia, stroke, severe brain injury, dementia, Parkinson's disease, cerebellar disease, organic brain syndrome or psychiatric disorders;
- •There are chronic obstructive pulmonary disease, interstitial lung disease, and clinically significant abnormalities in lung function tests;
- •After evaluation by the researchers, it was found that the subject had a large amount of uncontrollable serous fluid accumulation (such as pleural effusion, abdominal effusion, pericardial effusion).
研究组 & 干预措施
Treatment group
Experimental
CNCT19
干预措施: anti-CD19 CAR-T (Biological)
结局指标
主要结局
Dose limiting toxicity (DLT)
时间窗: Within 28 days of CNCT19infusion
Describe the adverse events of limiting further increases in the dose of CNCT19.
Adverse events
时间窗: Within 24 months after the treatment
Describe adverse events (AEs) and serious adverse events (SAEs) that are "likely" or "definitely" related to the studytreatment that occur at any time of 24 months after treatment.
Maximum tolerated dose
时间窗: From enrollment of the first subject to completion of follow-up of the last subject (up to 3 years)
Determine the optimal agent for CNCT19 at maximum tolerated dose.
次要结局
- Effectiveness evaluation(From enrollment of the first subject to completion of follow-up of the last subject (up to 5 years))
- Pharmacokinetic evaluation(Within 28 days of CNCT19 infusion)
研究者
TingBo Liang
Professor
Zhejiang University
研究点 (2)
Loading locations...
相似试验
招募中
1 期
Autologous CD19 Car T-Cell Therapy For Severe Refractory Systemic Lupus Erythematosus (SLE)Systemic Lupus Erythematous (SLE)NCT06710717National University of Malaysia5
尚未招募
1 期
CD19 CAR T Cells in Children and Adults With Relapsed or Refractory CD19 Positive B Cell MalignanciesRelapsed/Refractory B-Cell MalignanciesNCT04943016National Taiwan University Hospital12
进行中（未招募）
1 期
CD19-Car T Cell Therapy for the Treatment of Older Adults With Acute Lymphoblastic Leukemia in First RemissionB Acute Lymphoblastic LeukemiaNCT05707273City of Hope Medical Center18
招募中
1 期
Anti-CD19 Chimeric Antigen Receptor T Cells for Refractory Autoimmune DiseasesAutoimmune DiseasesNCT06688799Beijing GoBroad Hospital18
招募中
1 期
Clinical Trial of CD19-targeted CAR-T Therapy for Refractory Juvenile DermatomyositisJuvenile DermatomyositisNCT06569472Chongqing Precision Biotech Co., Ltd10